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CC BY-NC-ND liResolute zotarolimus-eluting stent (R-ZES). Drug-eluting stents with long lengths are
needed to ensure coverage of long lesions in some patients. Patients recruited from the
RESOLUTE US and RESOLUTE Asia studies were implanted with at least one 38-mm
R-ZES. Up to 2 lesions (in separate vessels) could be implanted with length £35 mm and
a reference vessel diameter of 3.0 to 4.2 mm. The primary end point was 1-year target lesion
failure, deﬁned as cardiac death, target vessel myocardial infarction, or clinically driven
target lesion revascularization. The 1-year target lesion failure rate using 1 vessel per
patient was compared with a performance goal (19%) derived from historical data. There
were 223 patients enrolled (n[ 269 lesions). The mean age was 60.9 – 10.9 years, 79% were
men, and 38% had diabetes. Target lesion failure rate using a single-vessel analysis was
4.5%, and the upper limit of the 1-sided 95% conﬁdence interval (7.5%) was less than the
performance goal of 19%. A secondary analysis using all lesions resulted in a target lesion
failure rate of 5.4% (upper limit of 1-sided 95% conﬁdence interval, 8.6%). Baseline char-
acteristics and clinical outcomes were similar between patients with and without diabetes.
The rate of probable or deﬁnite stent thrombosis was 0.9%. In conclusion, the 38-mm length
of the R-ZES was found to be safe and effective with a low rate of target lesion failure
and stent thrombosis and no differences in outcomes between patients with and without
diabetes. 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.
(Am J Cardiol 2013;112:1335e1341)
Drug-eluting stents have been found to be efﬁcacious and
cost-effective in complex disease subgroups such as long
lesions.1,2 Use of multiple, overlapping, ﬁrst-generation drug-
eluting stents has led to greater periprocedural myocardial
ischemia,3 stent fracture,4,5 and late stent thrombosis related
to impaired vascular healing6 compared with using a single
longer stent. Although studies of overlapping stents usingdrug-eluting stents have shown more prom-
the advantages of stenting long lesions with
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cense.fewer long stents remain. Drug-eluting stents with a length
of 38 mm can cover lesions of 35 mm using a single stent.
Studies of new-generation 38-mm drug-eluting stents have
demonstrated safety and efﬁcacy at 1-year follow-up.9,10 To
date, however, no study has reported data regarding the use
of the Resolute zotarolimus-eluting stent (R-ZES; Medtronic
Inc, Santa Rosa, California) in the 38-mm size. The safety
and efﬁcacy of the 38-mm R-ZES at 1 year
after implantation were investigated in a prospective sub-
study of the RESOLUTE US (R-US; ClinicalTrials.gov,
NCT00726453)11,12 and RESOLUTE Asia (R-Asia;
ClinicalTrials.gov, NCT01132456) studies, both of which
were part of the RESOLUTE Global Clinical Program.
Methods
In the RESOLUTE 38-mm substudy, patients were
enrolled from the R-US11,12 and R-Asia prospective,
observational, nonrandomized, multicenter trials. The
RESOLUTE 38-mm substudy was prospectively designed
to include patients requiring treatment of de novo lesions in
native coronary arteries from the R-Asia and R-US trials.
The study methods for R-US have been described previ-
ously.11,12 The study methods for the RESOLUTE 38-mm
substudy are brieﬂy described here.
Included patients were enrolled at 46 clinical sites in the
United States, Bangladesh, India, Hong Kong, Malaysia,
Singapore, and Thailand. Patients were enrolled in the R-US
from January 2010 through March 2011 and R-Asia fromwww.ajconline.orgr 
Table 1
Baseline characteristics (n ¼ 223 patients)
Characteristic Value
Age (yrs) 60.9  10.6
Men 176 (79)
Diabetes mellitus 84 (38)
Insulin-dependent diabetes mellitus 23 (10)
Hypertension (history)* 167 (75)
Hyperlipidemia (history)† 131 (59)
Current smoker 42 (19)
Family history of coronary artery disease 71 (37)
Previous MI 70 (32)
Previous percutaneous coronary intervention 61 (27)
Previous coronary artery bypass grafting 16 (7)
Cardiac status
Stable angina pectoris 76 (39)
Unstable angina pectoris 92 (47)
MI 26 (13)
MI = myocardial infarction.
Values are presented as mean age or number of patients (percentage).
* Deﬁned as a history of systolic blood pressure >140 mm Hg, diastolic
blood pressure >90 mg Hg, or requiring medication.
† Deﬁned as a history of cholesterol 200 mg/dl, low-density lipoprotein
>100 mg/dl, or requiring medication.
Table 2
Lesion and procedure characteristics (n ¼ 223 patients, 269 lesions)
Characteristic Value
Vessel disease status (patients)
Single 103/223 (46)
Double 81/223 (36)
Triple 39/223 (18)
Coronary artery location (patients)
Left anterior descending 116/223 (52)
Left circumﬂex 45/223 (20)
Right 99/223 (44)
Lesion location
Proximal 99/263 (38)
Mid 115/263 (44)
Distal 45/263 (17)
Ostial 4/263 (2)
Lesion length (mm)
<10 12/261 (5)
10e19.9 64/261 (25)
20 185/261 (71)
Branch vessel disease (lesions) 126/263 (48)
B2/C lesions 240/263 (91)
Lesion length (mm) 25.22  8.83
Reference vessel diameter (mm) 2.78  0.42
Minimum lumen diameter (mm) 0.80  0.36
Preprocedural stenosis (% of diameter) 71  12
Values arepresentedasnumber/total (percentage) of units ormeanunitsSD.
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Figure 1. Major clinical outcomes at 1 year, all patients (n ¼ 223). Analyses
are presented for all lesions in all vessels. For end point deﬁnitions, refer to
the Methods section. ARC def/prob ST ¼ Academic Research Con-
sortiumedeﬁnite or probable stent thrombosis; TLF ¼ total lesion failure;
TLR ¼ target lesion revascularization; TVMI ¼ target vessel myocardial
infarction.
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were performed in accordance with the International
Conference on Harmonisation Good Clinical Practices
guidelines. Institutional review boards approved clinical
activities at all sites, and all patients provided written
informed consent before enrollment.
Patients were 18 years old and considered to be
candidates for revascularization with a single target lesion or2 target lesions in separate vessels—at least 1 of which
required implantation with a 38-mm stent. Patients were
excluded for pregnancy, contraindications to drug-eluting
stents or drugs used in the study, and serious cardiovascular
or circulatory co-morbidities. Lesion length in enrolled
patients was 35 mm and reference vessel diameter was 3.0
to 4.2 mm.
Study stents were 38 mm in length and 3.0, 3.5, or 4.0 mm
in diameter. Patients were prescribed dual antiplatelet therapy
(aspirin and clopidogrel, ticlopidine, or prasugrel) for
a minimum of 6 months. Aspirin was continued indeﬁnitely
thereafter. Patient follow-up occurred at 30 days, 6, 9, and
12 months, with planned follow-up at 18 months and annu-
ally through 5 years.
Clinicalmonitoringwas conducted oncase report forms and
other documentation from 100% of patients enrolled in the
study. The Harvard Clinical Research Institute (Boston,
Massachusetts) conducted data management for R-US.
Medtronic, Inc. (the sponsor of both studies) conducted data
management for R-Asia. Data safety monitoring boards were
used for patient safety surveillance and clinical events
committees were used for event adjudication. These commit-
tees were coordinated by the Harvard Clinical Research Insti-
tute for the R-US and the Cardiovascular Research Foundation
for the R-Asia. The Harvard Clinical Research Institute Safety
Group prepared reports of pooled data between the studies for
review by the data safety monitoring boards.
The primary end point was target lesion failure at 1 year
after procedure, a composite of cardiac death, target vessel
myocardial infarction (MI; Q wave and noneQ wave), or
clinically driven target lesion revascularization by percuta-
neous or surgical methods.
All deaths were considered cardiac unless an unequivocal
noncardiac cause could be established. Major adverse
cardiac event was a composite of death, target vessel MI
(Q wave and noneQ wave), emergent coronary artery
bypass graft, or clinically driven repeat target lesion revas-
cularization by percutaneous or surgical methods. Target
vessel failure was a composite of cardiac death, target vessel
MI, or clinically driven target vessel revascularization by
percutaneous or surgical methods. Target vessel MI events
Table 3
Clinical outcomes through 1 year (n ¼ 223 patients, 269 lesions)
Outcome Months
1 (n ¼ 223) 6 (n ¼ 223) 9 (n ¼ 223) 12 (n ¼ 222)
Target lesion failure 10 (4.5) 10 (4.5) 11 (4.9) 12 (5.4)
Target vessel failure 10 (4.5) 11 (4.9) 14 (6.3) 15 (6.8)
Major adverse cardiac event 10 (4.5) 11 (4.9) 12 (5.4) 14 (6.3)
Cardiac death or target vessel MI 9 (4.0) 9 (4.0) 10 (4.5) 10 (4.5)
Death (all) 1 (0.4) 1 (0.4) 2 (0.9) 2 (0.9)
Cardiac only 1 (0.4) 1 (0.4) 2 (0.9) 2 (0.9)
Target vessel MI 8 (3.6) 8 (3.6) 8 (3.6) 8 (3.6)
Clinically driven target lesion revascularization 2 (0.9) 2 (0.9) 2 (0.9) 3 (1.4)
Target vessel revascularization 2 (0.9) 3 (1.3) 5 (2.2) 6 (2.7)
Early deﬁnite or probable stent thrombosis (0e30 days) 2 (0.9) NA NA NA
Late deﬁnite or probable stent thrombosis (1e12 mo) NA 0 0 0
NA ¼ not applicable; MI ¼ myocardial infarction.
Values are presented as number of patients (percentage). Analyses are presented for all lesions in all vessels. Stent thrombosis was deﬁned using Academic
Research Consortium criteria.14 For end point deﬁnitions, refer to the Methods section.
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Figure 2. Cumulative incidence of Academic Research Consortiumedeﬁnite or probable stent thrombosis through 1 year. For end point deﬁnitions, refer to the
Methods section.
Coronary Artery Disease/PCI With 38-mm R-ZES 1337presented in this study were adjudicated according to
extended historical criteria.13 Stent thrombosis was adjudi-
cated using Academic Research Consortium criteria.14
Lesion success was deﬁned as <50% residual stenosis of
the target lesion using any percutaneous method. Device
success was deﬁned as <50% residual stenosis of the target
lesion using only the assigned device. Procedure success
was deﬁned as <50% residual stenosis of the target lesion
and no in-hospital major adverse cardiac events.
The primary analysis of the pooled 38-mm substudy was
the 1-year target lesion failure rate compared with a pre-
speciﬁed performance goal that met the Food and Drug
Administration requirements. The performance goal was
derived from a logistic regression model based on all
patients implanted with the Endeavor zotarolimus-eluting
stent or Driver bare-metal stent (both of Medtronic Inc,
Santa Rosa, California) in the ENDEAVOR stent clinical
program.15e20 The predicted rates of target lesion failure
were calculated for patients with Endeavor zotarolimus-
eluting stent and bare-metal stent with a lesion length of 31
mm (average of 27 and 35 mm), and the performance goal
was set at 19%, which is >48% the expected target lesion
failure rate for patients with Endeavor zotarolimus-eluting
stent and preserves 51% of the beneﬁt compared with bare-metal stent. Therefore, the study hypothesis was that the
study population would have a 1-year target lesion failure
rate of <19%. A 1-sided upper 95% conﬁdence interval of
the 38-mm R-ZES 1-year target lesion failure rate was
calculated. If this upper limit was <19%, the clinical
objective would be considered to have been met.
The ENDEAVOR studies used to derive the performance
goal only from enrolled patients with single-vessel treat-
ment, but the RESOLUTE 38-mm substudy enrolled
patients with dual vessels treated. To ensure continuity with
the historical data, therefore, the primary analysis of the
target lesion failure end point was based on a single vessel
for all dual-vessel treated patients. For dual-vessel treated
patients with 38-mm R-ZES implanted in both vessels, 1
vessel or lesion was randomly selected as the target vessel or
lesion and the other was considered to be the nontarget
vessel or lesion. For dual-vessel treated patients with 1
vessel implanted with a 38-mm R-ZES and the other vessel
without a 38-mm R-ZES, the vessel or lesion implanted with
the R-ZES 38-mm was considered to be the target vessel or
lesion. A clinical event that was clearly not attributed to the
target vessel was not included in the target vessel analysis.
The target lesion failure rate counting all lesions was also
calculated as a secondary analysis.
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Figure 3. Major clinical outcomes at 1 year in patients with diabetes and without diabetes. Analyses are presented for all lesions in all vessels. p Values were
adjusted by propensity score for differences in baseline characteristics. For end point deﬁnitions, refer to the Methods section. ARC def/prob ST ¼ Academic
Research Consortiumedeﬁnite or probable stent thrombosis; TLF ¼ total lesion failure; TLR ¼ target lesion revascularization; TVMI ¼ target vessel
myocardial infarction.
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point analyses. Secondary end point analyses were con-
ducted using similar statistical techniques as in the primary
end point analysis.
At a 1-sided 0.05 level of signiﬁcance, a sample size of
199 evaluable patients yields 80% power to test the
hypothesis, assuming that the true 38-mm R-ZES 1-year
target lesion failure rate is 12.8%. Accounting for 10% loss
to follow-up rate, a total sample size of 221 patients was
needed.
Comparability between the cohorts of patients with
38-mm drug-eluting stents in R-US and R-Asia was assessed
using a 2-stage prespeciﬁed analysis. The ﬁrst stage assessed
the homogeneity of the covariates between the 2 cohorts.
Some of the baseline covariates were signiﬁcantly different
between the cohorts; those covariates were adjusted using
propensity scores to account for any covariate imbalances.
The second stage was to categorize patients into quintiles
based on this propensity score. The 85% conﬁdence interval
of propensity score quintileeadjusted difference between the
cohorts in target lesion failure at 1 year was calculated.
Because the 85% conﬁdence interval crossed zero, the 2
cohorts were considered poolable.
SAS, version 9.1, or higher (SAS Institute, Cary, North
Carolina) was used for all statistical analyses. p Values
<0.05 were considered statistically signiﬁcant.
Results
There were 223 patients included in the analysis, 114
from R-US (29 sites) and 109 from R-Asia (17 sites), with
a total of 269 lesions. A total of 222 (>99%) had follow-up
data through 1 year. Patients had a mean age of 60.9  10.6
years; most were men and a substantial portion had diabetes
mellitus (Table 1). Overall mean lesion length (n ¼ 261)
was 25.22  8.83 mm (Table 2).
The rate of lesion success was 100% (n ¼ 263 of 263),
and device success was achieved in 97% (n ¼ 257 of 265)of the lesions. The rate of procedure success was 96%
(n ¼ 210 of 218).
Dual antiplatelet therapy adherence was 92% (n ¼ 205 of
222) at 1 month, 91% (n ¼ 203) at 6 months, 90% (n ¼ 199)
at 9 months, and 90% (n ¼ 196) at 1 year.
The primary end point was met with a rate of target
lesion failure at 1 year of 4.5% (upper limit of 95% conﬁ-
dence interval 7.5%) using the prespeciﬁed single-vessel
analysis, which was signiﬁcantly lower than the perfor-
mance goal of 19%. The 1-year rate of target lesion failure
was 5.4% (upper limit of 95% conﬁdence interval 8.6%)
when all lesions in all vessels were included (Figure 1).
Most events (n ¼ 10 of 12) occurred in the ﬁrst 30 days. The
rate of deﬁnite or probable stent thrombosis was 0.9%
(n¼ 2), and both events occurred in the ﬁrst 30 days (Table 3
and Figure 2). There were no late deﬁnite or probable stent
thrombosis events. Both patients who experienced deﬁnite or
probable stent thrombosis events received dual antiplatelet
therapy without interruption after stent placement. There were
12 patients who experienced a side branch occlusion (5%), 5
of whom experienced a target vessel MI.
A post hoc analysis was conducted to analyze outcomes of
patients with (n¼ 84; n¼ 104 lesions) and without (n¼ 139;
n ¼ 165 lesions) diabetes. Baseline, lesion, and vessel char-
acteristics were similar between patients with and without
diabetes, except for reference vessel diameter (with diabetes,
2.68  0.43 mm; without diabetes, 2.84  0.41 mm; p ¼
0.002) and history of hypertension (with diabetes, 87%;
without diabetes, 68%; p = 0.001). Major clinical outcomes
were similar between patients with and without diabetes,
including target lesion failure (p ¼ 0.788) and deﬁnite or
probable stent thrombosis (p ¼ 0.201; Figure 3).
Discussion
Our study was a prospective international evaluation of
the safety and efﬁcacy of the 38-mm R-ZES. The pooled
data presented in this study were submitted to the Food and
Coronary Artery Disease/PCI With 38-mm R-ZES 1339Drug Administration for marketing approval of the 34-mm
and 38-mm R-ZES, which was granted in February 2013.
Despite disease complexity, the use of 38-mm R-ZES
resulted in a low target lesion failure rate that was signiﬁ-
cantly lower than the prespeciﬁed performance goal. We
also observed a low rate of deﬁnite or probable stent
thrombosis with no events after 30 days, indicating that the
38-mm R-ZES was safe through 1-year follow-up. A post
hoc analysis found that clinical and safety outcomes were
similar between patients with and without diabetes. Data
from R-US and R-Asia were found to be poolable using
a prespeciﬁed analysis, and the centralized and harmonized
adjudication processes were intended to mitigate bias.
The patients enrolled in our study had complex (clinical
and lesion) characteristics (Table 2). A substantial propor-
tion of patients had diabetes. Almost all lesions were class
B2 or C, and the mean percentage of preprocedural stenosis
was high. More than 70% of lesions were 20 mm in
length, as assessed by the core laboratory. Nevertheless,
rates of clinical and safety events were low.
The rates of target lesion failure and its component end
points at 1-year follow-up in our study were low (Table 3)
and consistent with the results of R-ZES in other studies in
the RESOLUTE Global Clinical Program. Although direct
comparisons cannot be made, the end point deﬁnitions for
components of target lesion failure were harmonized across
RESOLUTE studies. The 1-year rate in R-US (not including
patients enrolled in the 38-mm substudy) was 3.7%. In
RESOLUTE All Comers21 and RESOLUTE International
studies,22 which used all-comers designs, the rates of target
lesion failure were 8.3% and 7.0%, respectively. In these
latter studies, 18.2% (>18 mm, core angiographic labora-
tory) and 46.4% (>18 mm, visual estimation) of patients
had 1 long lesion. Neither study, however, included a 38-
mm R-ZES. The Percutaneous Treatment of LONG Native
Coronary Lesions With Drug-Eluting Stent-IV Trial
(LONG-DES-IV)23 speciﬁcally studied only long lesions
(25 mm), included the 38-mm R-ZES and had a 1-year
target lesion failure rate of 14.0%. Most events were
noneQ-wave target vessel MI (n ¼ 29 of 36), the deﬁnition
for which differed from our study.
The low rates of stent thrombosis, cardiac death, and
target vessel MI in our study conﬁrm the safety of the 38-
mm R-ZES through 1 year. There were only 2 early stent
thrombosis events and no late stent thrombosis events. Early
stent thrombosis is often assumed to be related to the
procedure rather than the device.14 Moreover, the rate of
deﬁnite or probable stent thrombosis (0.9%) in the RESO-
LUTE 38-mm substudy was also consistent with those
observed in R-US12 (0.1%), RESOLUTE24 (0%), RESO-
LUTE All Comers21 (2.3%), and RESOLUTE Interna-
tional22 (0.9%). The rate of cardiac death and target vessel
MI was also low in our study. The composite rate was 4.5%
at 1 year (n ¼ 10 of 222), with 2 cardiac deaths and 8 target
vessel MI events. One of the cardiac deaths and all of the
target vessel MI events occurred in the ﬁrst 30 days. The
rates of cardiac death and target vessel MI in our study were
consistent with RESOLUTE All Comers21 (1.3% and 4.2%,
respectively) and RESOLUTE International22 (1.4% and
3.1%, respectively). R-US12 reported a cardiac death rate of
0.7% and a target vessel MI rate of 1.4%. The lower meanlesion length in R-US (13.06  5.88 vs 25.22  8.83 mm)
may account for the lower rate of target vessel MI than the
rate observed in our study. RESOLUTE24 reported a cardiac
death rate of 0.7% but did not report target vessel MI rate
(total MI was 5.8%). The deﬁnitions for stent thrombosis,
cardiac death, and target vessel MI were harmonized across
these studies.
Our study had a greater proportion of patients with dia-
betes than other studies in the RESOLUTE Global Clinical
Program.25 A post hoc analysis of our study found no
differences in clinical outcomes between patients with and
without diabetes. Our study was not powered to assess such
differences, so these results may be considered exploratory.
Nevertheless, it is noteworthy that the rates of target lesion
failure (6.0%) and deﬁnite or probable stent thrombosis
(0%) among our study patients with diabetes were consistent
with those observed in a pooled analysis of the RESOLUTE
Global Clinical Program25 (target lesion failure rate: 6.6%,
stent thrombosis rate: 0.3%).
Our study has several limitations that should be noted.
This study pooled data from 2 observational, single-cohort
design studies (rather than a randomized design) with their
own protocols and clinical events committees. However, the
poolability of data derived from the R-US and R-Asia 38-mm
cohorts was statistically veriﬁed using prespeciﬁed tests.
Analysis of the pooled 38-mm R-ZES data from these 2
studies was prospectively planned, and thus, end point deﬁ-
nitions and adjudication processes were consistent between
the 2 studies. Finally, the primary outcome analysis was
designed to provide a robust assessment of the 38-mm stent’s
safety and efﬁcacy, despite the lack of a control group.
Two other new-generation drug-eluting stents are
commercially available in the 38-mm length and have been
studied through 1-year follow-up: XIENCE PRIME LL
everolimus-eluting stent (X-EES; Abbott Laboratories,
Santa Clara, California)9,26 and PROMUS Element ever-
olimus-eluting stent (P-EES; Boston Scientiﬁc Corp.,
Natick, Massachusetts).10,27 Patients in the X-EES study
were implanted with either 33- or 38-mm stent, and patients
in the P-EES study were implanted with either a 32- or
38-mm stent. All patients in our study were implanted with
a 38-mm R-ZES. Both these studies had a smaller sample
size (X-EES: n ¼ 104 and P-EES: n ¼ 102) than our study
(n ¼ 223). The mean age (R-ZES: 60.9 years; X-EES:
63.46 years; and P-EES: 65.9 years) and incidence of dia-
betes (R-ZES: 37.7%; X-EES: 35.6%; and P-EES: 30.0%)
seemed similar between studies, and all report similar rates
of target lesion failure to our study at 1-year follow-up. The
target lesion failure rate for X-EES was 7.7% with protocol-
deﬁned target vessel MI and 12.5% with Academic
Research Consortiumedeﬁnite target vessel MI.9,26 The
target lesion failure rate for P-EES was 3.1%; the deﬁnition
for target vessel MI was not reported.10,27 The differences
in end point deﬁnitions between these studies and ours do
not allow direct comparisons. Nevertheless, our study’s
target lesion failure rate appears to be consistent with those
observed in the aforementioned X-EES and P-EES studies.
The present study is the largest of a new-generation 38-mm
drug-eluting stent to date. Our study also provides the ﬁrst
data describing the 38-mm R-ZES as used in patients with
a wide range of clinical and lesion complexity.
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